In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Gilead pens $1.75bn deal with start-up Tango Therapeutics; deal expanded

03 Nov 2021

Executive Summary

Oncology start-up Tango Therapeutics Inc. signed its first major alliance, agreeing to discover and develop targeted immuno-oncology therapies with Gilead Sciences Inc.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Immuno-Oncology
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By